Imiquimod
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | DRUG-IMIQUIMOD |
|---|---|
| Type | Médicament |
| Alias | AldaraZyclaraІмiквімод |
| État | reviewed 2026-07-11 | pending_clinical_signoff |
| Maladies | DIS-PENILE-SCC |
| Sources | SRC-EAU-PENILE-2024 |
Faits sur les drogues
| Catégorie | Modifiant de réponse immunitaire topique (agoniste du récepteur à péage 7 [TLR7]) |
|---|---|
| Mécanisme | Synthetic imidazoquinoline TLR7 agonist. Binds TLR7 on plasmacytoid dendritic cells and monocytes/macrophages, triggering NF-κB-mediated release of IFN-α, TNF-α, and other pro-inflammatory cytokines. Induces a local Th1-skewed innate + cell-mediated immune response against virally-infected or dysplastic epithelium; not directly cytotoxic or antiviral itself. Used topically for HPV-associated and field- cancerization lesions (external genital warts, actinic keratosis, superficial BCC) where local immune-mediated clearance is desired. |
| Dose typique | Genital warts (on-label): 5% cream applied 3x/week (e.g., Mon/Wed/Fri) at bedtime, washed off after 6-10 hours, for up to 16 weeks. Actinic keratosis: 5% cream 2x/week for 16 weeks (face/scalp) or 3.75% cream once daily for two 2-week cycles. Off-label penile intraepithelial neoplasia / Tis: dosing extrapolated from genital-wart / vulvar-HSIL protocols (typically 3x/week for 6-16 weeks with response-guided duration) — individualize with dermatology/urology; not FDA-labeled for this indication. |
| Ukraine enregistrée | Vrai |
| NSZU remboursé | Faux |
| Ukraine vérifiée pour la dernière fois | 2026-07-11 |
Notes
STUB — drafted for DIS-PENILE-SCC organ-sparing pathway (topical field therapy option for Tis / penile intraepithelial neoplasia, alternative to topical 5-FU). Pending clinical co-lead signoff (CHARTER §6.1; dev-mode-exempted for draft merge). Cross-disease reusable — imiquimod was already mentioned in prose (not as a formal Drug entity) across BCC-related and skin-cancer-prevention/surveillance indications in this KB; this is the first formal DRUG-IMIQUIMOD entity.
Utilisé par
Indication
IND-PENILE-SCC-1L-ORGAN-SPARING- IND-PENILE-SCC-1L-ORGAN-SPARING